Developing melanoma therapeutics: overview and update (Q38081406)

28 August 2017

title

Developing melanoma therapeutics: overview and update (English)

1 reference

28 August 2017

John B Korman

1

1 reference

28 August 2017

David E Fisher

series ordinal

2

1 reference

28 August 2017

publication date

13 February 2013

1 reference

Wiley interdisciplinary reviews. Systems biology and medicine

28 August 2017

published in

1 reference

28 August 2017

volume

5

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

257-271

1 reference

A brief history of melanoma: from mummies to mutations

28 August 2017

cites work

1 reference

Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies

21 January 2018

1 reference

A landscape of driver mutations in melanoma

21 January 2018

1 reference

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

21 January 2018

1 reference

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background

21 January 2018

1 reference

Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist

21 January 2018

1 reference

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

21 January 2018

Cancer statistics, 2012

1 reference

Recent trends in incidence of cutaneous melanoma among US Caucasian young adults

21 January 2018

1 reference

Time to get serious about skin cancer prevention

21 January 2018

1 reference

Systematic review of medical treatment in melanoma: current status and future prospects.

21 January 2018

1 reference

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

Genomic medicine--a primer

21 January 2018

1 reference

From genes to drugs: targeted strategies for melanoma

21 January 2018

1 reference

Melanoma: from mutations to medicine

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance

21 January 2018

1 reference

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

Progression of RAS-mutant leukemia during RAF inhibitor treatment

21 January 2018

1 reference

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

21 January 2018

1 reference

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

21 January 2018

1 reference

Resistance to MEK Inhibitors: Should We Co-Target Upstream?

21 January 2018

1 reference

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

21 January 2018

1 reference

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

21 January 2018

1 reference

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

21 January 2018

1 reference

Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage

21 January 2018

1 reference

MDM4 is a key therapeutic target in cutaneous melanoma

21 January 2018

1 reference

A Melanoma Molecular Disease Model

21 January 2018

1 reference

Melanoma as a model tumour for immuno-oncology

21 January 2018

1 reference

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma

21 January 2018

1 reference

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

21 January 2018

1 reference

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

Integrated NY-ESO-1 antibody and CD8 T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Trial Watch: Adoptive cell transfer immunotherapy

21 January 2018

1 reference

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

21 January 2018

1 reference

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

21 January 2018

1 reference

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/WSBM.1210

1 reference

28 August 2017

1 reference